BCL2A1 and hematopoietic and lymphoid system neoplasm: Previous studies have demonstrated that these two drugs can inhibit tumor progression (68, 69), and another study has confirmed that inhibition of BCL2A1 expression increases the sensitivity of blood cancers to imatinib (70).